Scholars@Duke publication: 636 Patient-reported distress with immunotherapy-based first-line treatment for mNSCLC: a real-world evidence study

636 Patient-reported distress with immunotherapy-based first-line treatment for mNSCLC: a real-world evidence study

Publication , Conference

Bodd, M; Locke, S; Antonia, S; Crawford, J; Hartman, J; Herring, K; Ready, N; Stinchcombe, T; Troy, J; Williams, C; Wolf, S; Clarke, J; LeBlanc, T

Published in: Journal for ImmunoTherapy of Cancer

November 2021

Published version (DOI) Publisher Link

Duke Scholars

Author Jeffrey Crawford Medicine, Medical Oncology

Author Jesse David Troy Biostatistics & Bioinformatics, Division of Biostatistics

Author Thomas William LeBlanc Medicine, Hematologic Malignancies and Cellular Therapy

Published In

Journal for ImmunoTherapy of Cancer

DOI

10.1136/jitc-2021-sitc2021.636

EISSN

2051-1426

Publication Date

November 2021

Volume

Issue

Suppl 2

Start / End Page

A665 / A665

Publisher

BMJ

Related Subject Headings

3211 Oncology and carcinogenesis
3204 Immunology

Citation

APA

Chicago

ICMJE

MLA

NLM

Bodd, M., Locke, S., Antonia, S., Crawford, J., Hartman, J., Herring, K., … LeBlanc, T. (2021). 636 Patient-reported distress with immunotherapy-based first-line treatment for mNSCLC: a real-world evidence study. In Journal for ImmunoTherapy of Cancer (Vol. 9, pp. A665–A665). BMJ. https://doi.org/10.1136/jitc-2021-sitc2021.636

Bodd, Monica, Susan Locke, Scott Antonia, Jeffrey Crawford, John Hartman, Kris Herring, Neal Ready, et al. “636 Patient-reported distress with immunotherapy-based first-line treatment for mNSCLC: a real-world evidence study.” In Journal for ImmunoTherapy of Cancer, 9:A665–A665. BMJ, 2021. https://doi.org/10.1136/jitc-2021-sitc2021.636.

Bodd M, Locke S, Antonia S, Crawford J, Hartman J, Herring K, et al. 636 Patient-reported distress with immunotherapy-based first-line treatment for mNSCLC: a real-world evidence study. In: Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. A665–A665.

Bodd, Monica, et al. “636 Patient-reported distress with immunotherapy-based first-line treatment for mNSCLC: a real-world evidence study.” Journal for ImmunoTherapy of Cancer, vol. 9, no. Suppl 2, BMJ, 2021, pp. A665–A665. Crossref, doi:10.1136/jitc-2021-sitc2021.636.

Bodd M, Locke S, Antonia S, Crawford J, Hartman J, Herring K, Ready N, Stinchcombe T, Troy J, Williams C, Wolf S, Clarke J, LeBlanc T. 636 Patient-reported distress with immunotherapy-based first-line treatment for mNSCLC: a real-world evidence study. Journal for ImmunoTherapy of Cancer. BMJ; 2021. p. A665–A665.

Published In

Journal for ImmunoTherapy of Cancer

DOI

10.1136/jitc-2021-sitc2021.636

EISSN

2051-1426

Publication Date

November 2021

Volume

Issue

Suppl 2

Start / End Page

A665 / A665

Publisher

BMJ

Related Subject Headings

3211 Oncology and carcinogenesis
3204 Immunology